Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13833MR)

This product GTTS-WQ13833MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13833MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7990MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ3985MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ622MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ3123MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ4371MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ10391MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ2864MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ661MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW